BOSTON, April 3 /PRNewswire/ -- Aida Pharmaceuticals (BULLETIN BOARD: AIDA) , one of mainland China's leading pharmaceutical companies, announced today that it has retained Equity Performance Group to direct a comprehensive investor relations campaign. Equity Performance Group will provide Aida Pharmaceuticals with ongoing investor relations and business communications services tailored to increase the marketability and exposure of its stock to the financial community.
About Aida Pharmaceuticals
Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO9002 certified for quality assurance and ISO14000 certified for ecologically-friendly practices. Aida is now producing and marketing a patented prescription drug in China, etimicin sulfate. It is the first antibiotic developed in China and is regarded as a category "A" drug by the State Food and Drug Administration of China.
About The Equity Performance Group:
The Equity Performance Group provides publicly traded micro-cap companies with services to enhance their trading performance. The Company's advisory services and proactive campaigns are custom designed to dramatically improve each client's exposure by communicating financial catalysts; transition and turnaround strategies; and breaking news to a broad retail and institutional audience within the financial community. Improved trading performance and an expanding shareholder base facilitate capital raises, secondary offerings, merger and acquisition activity, float diversification, and can ensure that listing/exchange requirements are continuously met.
Aida Pharmaceuticals, Inc.
31 Dingjiang Road
Jianggan District
Hangzhou, China 310016
Investor Relations:
Equity Performance Group
Gary Geraci
(617) 723-2373
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995:
This press release includes certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995. These statements are based on Aida Pharmaceuticals, Inc.'s management's current expectations and are subject to risks and uncertainties and changes in circumstances. All forward-looking statements included in this press release are based upon information available to Aida Pharmaceuticals, Inc. as of the date of the press release, and it assumes no obligation to update or alter its forward looking statements whether as a result of new information, future events or otherwise. These forward-looking statements may relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact. Further information on risks or other factors that could affect Aida Pharmaceuticals, Inc.'s results of operations is detailed in its filings with the United States Securities and Exchange Commission available at http://www.sec.gov/.
Equity Performance Group (EPG) has been engaged by AIDA Pharmaceuticals and serves as the company's special advisor. EPG has received fees for services, including the creation and distribution of materials. Equity Performance Group is contracted by AIDA Pharmaceuticals for $7,500 per month and could receive up to 150,000 shares of restricted stock based on the attainment of pre-determined performance metrics. EPG- at the client's election - could also receive cash, or shares of common stock from a third party for marketing purposes at a future point in time. Equity Performance Group reserves the right to sell any acquired shares at its sole discretion without cause or qualification. This is not an offer to buy or sell securities. Information or opinions are presented solely for informative purposes, and are not intended nor should they be construed as investment advice. Shares of the profiled company mentioned herein may carry a high investment risk, potentially loosing some or all of their future value; readers should carefully review the company thoroughly with their registered investment advisor or registered stockbroker. We are not liable for any investment decisions by our readers. Past performance is not an indicator of future results. Certain statements in this publication relate to the company's expectations with regard to the future impact on the company's results are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The results anticipated by any or all of these forward-looking statements may not occur. We encourage our readers to invest carefully and read the investor information available at the web sites of the U.S. Securities and Exchange Commission (SEC) at http://www.sec.gov/ and the National Association of Securities Dealers (NASD) at http://www.nasd.com/. All information within these publications is qualified in its entirety by the detailed information and financial statements of the featured company contained in its regulatory filings with the SEC. The information contained herein does not purport to be a complete study of the featured Company or other companies mentioned. Information used and statements of fact have been obtained from the featured Company and other sources, but not verified nor guaranteed by Equity Performance Group as to completeness or accuracy.
